<DOC>
	<DOCNO>NCT01856101</DOCNO>
	<brief_summary>The mTOR ( mammalian Target Rapamycin ) protein center mTOR pathway play important role cell growth , proliferation , survival angiogenesis sense integrate energetic signal cellular environment . The mTOR protein compose two complex , mTOR complex 1 ( mTOR C1 ) mTOR complex 2 ( mTOR C2 ) . In regard mTOR pathway dysregulations observe TCC development , rational test BEZ23 advance TCC . BEZ235 pan-class I PI3K inhibitor , addition , bind catalytic site mTOR , inhibit mTOR C1 mTOR C2 .</brief_summary>
	<brief_title>Study BEZ235 Monotherapy Patients With Transitional Cell Carcinoma After Failure Platinum Based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<criteria>1 . Patients histologically cytologicallyconfirmed locally advanced metastatic TCC amenable curative surgery radiation . 2 . Documented disease progression ( accord RECIST 1.1 criterion ) first line platinumbased therapy ( give neoadjuvant/adjuvant palliative setting ) . 3 . An interval &gt; 4 week since last anticancer treatment . 4 . Archival paraffinembedded tumor tissue ( block least 20 unstained slide ) primary tumor and/or metastasis . The recent archival tissue mandatory . Recidive disease lead perform possible novel biopsy , major oncogenic difference find primary tumor secondary lesion . 5 . At least one measurable lesion MRI CTscan 6 . ECOG performance status 01 , stable medical condition 7 . Patients must adequate organ function : Hemoglobin ≥ 9 g/100 ml , neutrophils ≥ 1,000/mm3 , platelet ≥ 100,000/mm , INR ≤ 1.5 , total serum bilirubin ≤ 1.5 x ULN , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3 x ULN ( &lt; 5.0 x ULN hepatic metastasis present ) , creatinine £1.5 x ULN , fast plasma glucose &lt; 140mg/dl , HbA1c &lt; 8 % . 8 . Patients must 18 year old able give write informed consent . 9 . Signed informed consent prior begin protocol specific procedure 1 . Non TCC bladder cancer 2 . More 2 prior chemotherapy regimen give palliation . 3 . Concurrent malignancy previous malignancy last 3 year prior start study treatment ( exception history adequately treat cervical carcinoma situ nonmelanoma skin cancer ) 4 . Patient active uncontrolled symptomatic central nervous system ( CNS metastases ) . 5 . Significant active cardiac disease include uncontrolled high blood pressure , unstable angina , congestive heart failure , myocardial infarction within previous 6 month , serious cardiac arrhythmia . 6 . Other uncontrolled medical condition ( active infection require antibiotic , bleed disorder , uncontrolled diabetes … ) 7 . Other concomitant anticancer therapy . 8 . Previous therapy PI3K and/or mTOR inhibitor ( sirolimus , temsirolimus , everolimus ) 9 . Concomitant drug coumarin warfarin , drug know induce torsade de pointe , drug know moderate strong inhibitor inducer CYP3A4 10 . Pregnancy risk pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>TCC</keyword>
	<keyword>Failure platinum base chemotherapy</keyword>
</DOC>